Joshua A. Kazam is Director at Allogene Therapeutics, Inc. (ALLO). They have made 8 open-market trades across 4 companies since 2008, most recently 2026-06-18.
CIK 0001221355
8 open-market purchases totalling $382K since 2008, never a sale. Across 8 scored buys the stock is down 4.2% at ninety days, and 3.4 points behind the S&P over the same stretch.
8 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 0% | 50% | 50% |
| Avg Move | -7.0% | -2.5% | -4.2% |
| Alpha | -28.5% | -2.6% | -3.4% |
| Scored | 8 | 8 | 8 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ALLO | BUY | 2022-01-12 | 2022-01-14 | $12.60 | $189K | -19.4% | -23.4% | -36.7% |
| EAGL | BUY | 2019-03-05 | 2019-03-05 | $10.20 | $51K | -2.3% | -2.3% | -2.3% |
| EAGL | BUY | 2019-03-01 | 2019-03-01 | $10.13 | $101K | -0.6% | -0.7% | -0.7% |
| CAPR | BUY | 2015-01-21 | 2015-01-22 | $3.52 | $25K | -32.6% | -3.3% | -3.3% |
| NLTX | BUY | 2009-03-12 | 2009-03-13 | $0.75 | $383 | -0.3% | +2.4% | +2.4% |
| NLTX | BUY | 2008-12-16 | 2008-12-16 | $1.15 | $4K | -0.3% | +2.4% | +2.4% |
| NLTX | BUY | 2008-12-15 | 2008-12-15 | $1.05 | $3K | -0.3% | +2.4% | +2.4% |
| NLTX | BUY | 2008-12-11 | 2008-12-12 | $1.13 | $9K | -0.3% | +2.4% | +2.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
| LTCH |
| 30,000 |
| — |
| Total | $16.9M |
Shares reported on the most recent Form 4, priced at the 2026-06-23 close. 1 holding could not be priced and is excluded from the total.